Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2013 17:45 ET | Source: biOasis Technologies Inc.

Option Grant-biOasis Technologies Inc.

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 4, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI) (the "Company") announces that, pursuant to the terms of its Stock Option Plan, the...
November 12, 2013 09:00 ET | Source: biOasis Technologies Inc.

Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 12, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI)(OTCBB:BIOAF), a pioneering biopharmaceutical company focused on overcoming the...
October 17, 2013 09:00 ET | Source: biOasis Technologies Inc.

biOasis Presents Research Results on BT2111 (Transcend-Trastuzumab) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 17, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI) is pleased to announce that preclinical data on its proprietary BT2111 program...
October 01, 2013 09:00 ET | Source: biOasis Technologies Inc.

biOasis Engages Liolios Group to Lead New Investor Relations Program

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 1, 2013) - biOasis Technologies, Inc. (TSX VENTURE:BTI)(OTCBB:BIOAF), a pioneer in the delivery of therapeutics across the blood-brand...
September 04, 2013 14:04 ET | Source: biOasis Technologies Inc.

biOasis to Present at the 2013 Gateway Conference on September 10

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 4, 2013) - biOasis Technologies, Inc. (TSX VENTURE:BTI) (OCTQX:BIOAF), a biopharmaceutical company focused on the delivery of...
August 07, 2013 09:00 ET | Source: biOasis Technologies Inc.

biOasis Technologies Inc. Announces Notice of Allowance for Key Lysosomal Storage Disease Patent From the US Patent and Trademark Office

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 7, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI), today announced that it has received a Notice of Allowance from the U.S. Patent...
June 18, 2013 09:00 ET | Source: biOasis Technologies Inc.

CEO Letter to Shareholders

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 18, 2013) - biOasis Technologies Inc., (TSX VENTURE:BTI) an industry-leading provider of technology to potentially deal with the unmet...
April 09, 2013 09:00 ET | Source: biOasis Technologies Inc.

biOasis's Update on the BT2111-Herceptin(R) Program

VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 9, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today an update on the advancement of its anti-cancer product candidate...
February 13, 2013 14:00 ET | Source: biOasis Technologies Inc.

biOasis Named to 2013 TSX Venture 50(R)

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 13, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI) announces it has been named one of the 2013 TSX Venture 50® companies. The...
February 07, 2013 09:00 ET | Source: biOasis Technologies Inc.

biOasis Announces Positive Anti-Tumour Efficacy Data

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 7, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that its Transcend-Herceptin® Conjugate (BT2111) product...